Thalidomide provided significant protection against tri nitro benzene sulfonic acid induced colitis. Combination therapy also reduced colonic inflammation and all the biochemical parameters (myeloperoxidase assay, malondialdehyde assay and tumor necrosis factor-alpha, estimation) were significant as compared to control as well as thalidomide alone treated group. Combination therapy showed additive effect of thalidomide which restored lipid peroxidation as well as reduced myeloperoxidase and TNF-a towards the normal levels. Morphological and histological scores were significantly reduced in combination groups. In experimental model of colitis, oral administration of thalidomide (150 mg/kg) alone as well as its combination with sulfasalazine (360 mg/kg) significantly reduced the colonic inflammation. The results indicate the additive effect of thalidomide with sulfasalazine in rat colitis model which requires further confirmation in human studies.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A novel approach with tofacitinib for the management of keratoderma blennorrhagicum in reactive arthritis: a case report.
Front Immunol
July 2024
Department of Rheumatology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Article Synopsis
- Reactive arthritis (ReA) is a type of arthritis related to previous infections and features arthritis, skin symptoms like keratoderma blennorrhagicum, and other manifestations.
- A case study detailed in the article illustrates ReA following a urinary tract infection, initially treated with sulfasalazine and thalidomide, which helped with arthritis but not skin issues.
- Switching to tofacitinib showed significant improvement in the persistent skin rash after 20 days, highlighting its potential effectiveness in treating challenging cases of ReA with severe skin involvement.
Clinical Features of Paediatric Inflammatory Epidermolysis Bullosa Acquisita: A Case Series Study.
Acta Derm Venereol
January 2024
Department of Dermatology, Peking University First Hospital, Beijing, China; National Clinical Research Center for Skin and Immune Diseases, Beijing, China; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.
Article Synopsis
- The study focuses on epidermolysis bullosa acquisita (EBA), a rare autoimmune skin condition that occurs infrequently in children, examining 7 pediatric patients aged 16 and under.
- All patients showed inflammatory EBA, with some displaying symptoms similar to bullous pemphigoid, and unique histopathological features such as specific neutrophil distributions.
- Treatment involved glucocorticoids and other medications like dapsone, thalidomide, and sulfasalazine, all of which were effective, but relapses often happened when glucocorticoid dosages were reduced or stopped, indicating a need for tailored treatment and follow-up for children with this condition.
Cause analysis of conversion to biologics in spondyloarthritis patients with poor response to conventional treatment.
Clin Rheumatol
December 2023
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Objective: We sought to investigate the reasons why spondyloarthritis (SpA) patients failed to respond to non-steroidal anti-inflammatory drugs (NSAIDs) and conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) and the influences of different initial cDMARDs on the likelihood of a switch to biologics.
Methods: SpA patients were divided into a conventional drug maintenance group and a biologics conversion group to determine the causes of conversion to biologics. Then, we divided all patients into three groups according to different initial cDMARDs, NSAID monotherapy, NSAID + (sulfasalazine or thalidomide) double combination, and NSAID + sulfasalazine + thalidomide triple combination therapy groups, to clarify the influence of initial treatment on later conversion to biologics.
[Current aspects of antirheumatic therapy in pregnancy planning, during pregnancy and breastfeeding].
Z Rheumatol
October 2021
Universitätsklinik für Rheumatologie und Immunologie, Inselspital Bern, Freiburgstraße 18, 3010, Bern, Schweiz.
Active rheumatic disease is a known factor for increased fetomaternal risks during pregnancy. Remission or inactive disease should therefore be targeted to reduce these risks by using pregnancy-compatible antirheumatic drugs as recommended by international guidelines. Teratogenic antirheumatic drugs, such as mycophenolate, methotrexate, cyclophosphamide and thalidomide should be stopped about 3 months prior to conception.
View Article and Find Full Text PDFClinical characteristics and genetic analysis of A20 haploinsufficiency.
Pediatr Rheumatol Online J
May 2021
Capital Institute of Pediatrics, 2 yabao road, Chaoyang District, Beijing, China.
Purpose: To evaluate the clinical and genetic characteristics of 3 children with Haploinsufficiency of A20 (HA20).
Methods: The clinical and genetic testing data of 3 children with HA20 treated at Capital Institute of Pediatrics (CIP) between August 2016 and October 2019 were retrospectively analysed.
Result: Patient 1 presented with arthritis and inflammatory bowel disease, patient 2 presented with axial spinal arthritis and lupus-like syndrome, and patient 3 presented with recurrent oral ulcers, gastrointestinal ulcers, and perianal abscesses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!